Review of esophageal cancer outcomes at Memorial Sloan Kettering Cancer Center

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the prognostic significance of the circumferential resection margin (CRM) in patients with esophageal cancer who have undergone esophagectomy. It focuses on patients with histologically confirmed esophageal adenocarcinoma or squamous cell carcinoma, specifically those with pathologic staged T3 tumors. By analyzing the outcomes of these patients, the study aims to clarify the impact of CRM on survival rates, which remains a controversial topic in the field. The findings could provide valuable insights into the management of esophageal cancer post-surgery.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed esophageal adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) undergoing esophagectomy
* Pathologic staged T3 tumors (pT3)

Exclusion Criteria:

* Pathologic staged T0-2 (pT0-2) or T4 tumors (pT4)
* Patients with histologic types other than EAC or ESCC, dysplasia or carcinoma in situ without tumor invasion,
* Patients undergoing salvage esophagectomy
* Evidence of distant metastatic disease
* Patients with a positive proximal or distal margin

Where it's running

• Memorial Sloan Kettering Cancer Center (All Protocol Activities)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Daniela Molena, MD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Daniela Molena, MD
• Email: molenad@mskcc.org
• Phone: 212-639-3870

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CA-4948 combined with chemotherapy and immunotherapy for advanced gastric and esophageal cancer

  This study is testing a new treatment combining CA-4948 with chemotherapy and immunotherapy to see if it helps people with advanced stomach and esophageal cancer who haven't had other treatments yet.

  Recruiting Phase 1 Washington University School of Medicine · St Louis, Missouri · NCT05187182

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

• Survey for patients with esophageal cancer and upper digestive diseases

  This study is trying to gather information from patients with esophageal cancer and other upper digestive issues to see how they are doing after treatment and improve future care.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT02530983

• PF-08098488 in adults with advanced solid tumors

  This study tests PF-08098488 in adults whose cancer has progressed or returned after prior treatment.

  Recruiting at 4 sites Phase 1 Pfizer · Grand Rapids, Michigan and 3 other locations · NCT07903415

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• MGC030 in adults with advanced solid tumors

  This trial tests MGC030 in adults with advanced urothelial, gastric/GEJ, esophageal, colorectal, gastric, pancreatic, or GEJ cancers to see if it is safe and whether it can shrink tumors or stop growth.

  Recruiting Phase 1 MacroGenics · Lake Success, New York · NCT07822399

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.